LENZ Therapeutics Management
Management criteria checks 0/4
LENZ Therapeutics' CEO is Eef Schimmelpennink, appointed in Mar 2021, has a tenure of 4.17 years. total yearly compensation is $6.98M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $1.45M. The average tenure of the management team and the board of directors is 1.2 years and 1.2 years respectively.
Key information
Eef Schimmelpennink
Chief executive officer
US$7.0m
Total compensation
| CEO salary percentage | 8.69% |
| CEO tenure | 4.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.2yrs |
| Board average tenure | 1.2yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$48m |
| Dec 31 2024 | US$7m | US$607k | -US$50m |
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$74m |
| Dec 31 2023 | US$3m | US$537k | -US$70m |
| Sep 30 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$1m | US$508k | -US$11m |
Compensation vs Market: Eef's total compensation ($USD6.98M) is above average for companies of similar size in the US market ($USD3.97M).
Compensation vs Earnings: Eef's compensation has increased whilst the company is unprofitable.
CEO
Eef Schimmelpennink (52 yo)
Mr. Evert B. Schimmelpennink, also known as Eef, serves as Director of Pipeline Therapeutics, Inc. since February 2022. He serves as an Independent Director at Contineum Therapeutics, Inc. since January 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.2yrs | US$6.98m | 0.17% $ 1.5m | |
| Co-Founder & Director | no data | US$365.01k | 2.2% $ 18.3m | |
| Chief Financial Officer | 1.2yrs | US$3.17m | 0.011% $ 94.2k | |
| Chief Medical Officer | 1.2yrs | US$2.04m | 0.35% $ 2.9m | |
| Vice President of Sales | no data | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Chief Commercial Officer | 1.2yrs | US$795.02k | 0.017% $ 139.8k | |
| Senior Vice President of Manufacturing Operations | no data | no data | no data | |
| Senior Vice President of Regulatory & Clincal Operations | no data | no data | no data |
Experienced Management: LENZ's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.2yrs | US$6.98m | 0.17% $ 1.5m | |
| Co-Founder & Director | 1.2yrs | US$365.01k | 2.2% $ 18.3m | |
| Independent Director | 1.2yrs | US$381.40k | 0% $ 0 | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Chairman | 1.2yrs | US$396.22k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$380.23k | 0% $ 0 | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.6yrs | US$374.77k | 0% $ 0 | |
| Member of Medical Advisory Board | no data | no data | no data |
Experienced Board: LENZ's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 07:43 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LENZ Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Matthew Caufield | H.C. Wainwright & Co. |